to Oslo Medtech
Register here to subscribe to our newsletter!
Generating innovation. For better living and health.
Medistim ASA, a Norwegian company that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the National Institute for Health and Clinical Excellence (NICE) today has accepted the health economics derived from routine usage of the VeriQ system for assessing graft blood flow during coronary artery bypass graft (CABG) surgery, compared to clinical assessment alone.
NICE reports an estimated cost saving of more than £115 per patient. NICE also support the clinical evidence, suggesting reduction of early graft failure, stroke, myocardial infarction or recurrent angina.
Press release in English, click here. Press release in Norwegian, click here.